Biofrontera about to crush it come January

Biofrontera Grows Revenues and Improves Financial Position in First Half 2017
Leverkusen, Germany, August 31, 2017 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer , today reported its financial results for the second quarter and first half ended June 30, 2017 and provided an update on recent operational and clinical developments.
“The first half of 2017 proved to be a great success as we grew our total revenues by 193% year-over-year to €5 million, driven primarily by our sales in the U.S. In the second quarter we took additional steps to further strengthen our momentum and improve the efficiency and effectiveness of our U.S. sales operations to drive adoption of Ameluz® by dermatologists. Additionally, as we seek to expand our market opportunity, we remain excited about the prospects for a basal cell carcinoma label extension with an efficient and less costly clinical development plan recently agreed upon with the FDA. In Europe, the approval from the European Commission for a label extension to include BCC reinforces our position in the PDT market and expands the reach of Ameluz® into hospitals where dermatologists are based in most countries in Europe. We also look forward to a positive opinion from the European Medicines Agency by the end of 2017 or early 2018 for our recently submitted application to expand the label of Ameluz® to include daylight-PDT. With the support of recent capital raises and the loan from the European Investment Bank, we believe that we have significant opportunities to continue to grow in all of our markets and expand our indications in order to support future growth,” commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera.
Second Quarter and First Half 2017 Financial Highlights:
• Sales increased by 193% to €5.0 million in H1 2017, compared to €1.7 million in the same period 2016.
• Generated €2.4 million in revenues in U.S. in H1 2017, in line with expectations.
• Research and development costs increased to €2.2 million in H1 2017 (up 18%), mainly due to costs incurred as part of the development partnership with Maruho.
• Net loss was €8.1 million in H1 2017

What is happening in the field is not acceptable. PDT season is NOW. The field needs leadership, 2018 has been spent entirely putting out Holm/ Rose created fires. If not resolved quickly, the problem is on your watch. Biofrontera: where opportunities come to be squandered.